Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
The post and conversation are about the use of oral Minoxidil (Min), Finasteride (Fin), and RU58841 for hair loss treatment, with mixed opinions on their safety and effectiveness.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
The conversation is about someone considering a hair transplant due to ineffective hair loss treatments, with suggestions ranging from trying a hairpiece to continuing with medications like finasteride and minoxidil, and waiting for new treatments. Some advise against a transplant due to the extent of hair loss and the cost, while others share different views on the effectiveness of transplants and non-surgical options.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trialsin China and Phase II in the U.S., and the treatment also shows promise for acne.